Cargando…

Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer

BACKGROUND: Controversy exists regarding the optimal sequence of chemotherapy among women with operable node‐negative breast cancers with high‐risk tumor biology. We evaluated national patterns of neoadjuvant chemotherapy (NACT) use among women with early‐stage HER2+, triple‐negative (TNBC), and hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Prakash, Ipshita, Neely, N. Ben, Thomas, Samantha M., Sammons, Sarah, Blitzblau, Rachel C., DiLalla, Gayle A., Hyslop, Terry, Menendez, Carolyn S., Plichta, Jennifer K., Rosenberger, Laura H., Fayanju, Oluwadamilola M., Hwang, E. Shelley, Greenup, Rachel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855910/
https://www.ncbi.nlm.nih.gov/pubmed/34989142
http://dx.doi.org/10.1002/cam4.4517
_version_ 1784653737361408000
author Prakash, Ipshita
Neely, N. Ben
Thomas, Samantha M.
Sammons, Sarah
Blitzblau, Rachel C.
DiLalla, Gayle A.
Hyslop, Terry
Menendez, Carolyn S.
Plichta, Jennifer K.
Rosenberger, Laura H.
Fayanju, Oluwadamilola M.
Hwang, E. Shelley
Greenup, Rachel A.
author_facet Prakash, Ipshita
Neely, N. Ben
Thomas, Samantha M.
Sammons, Sarah
Blitzblau, Rachel C.
DiLalla, Gayle A.
Hyslop, Terry
Menendez, Carolyn S.
Plichta, Jennifer K.
Rosenberger, Laura H.
Fayanju, Oluwadamilola M.
Hwang, E. Shelley
Greenup, Rachel A.
author_sort Prakash, Ipshita
collection PubMed
description BACKGROUND: Controversy exists regarding the optimal sequence of chemotherapy among women with operable node‐negative breast cancers with high‐risk tumor biology. We evaluated national patterns of neoadjuvant chemotherapy (NACT) use among women with early‐stage HER2+, triple‐negative (TNBC), and high‐risk hormone receptor‐positive (HR+) invasive breast cancers. METHODS: Women ≥18 years with cT1‐2/cN0 HER2+, TNBC, or high recurrence risk score (≥31) HR+ invasive breast cancers who received chemotherapy were identified in the National Cancer Database (2010–2016). Cochran‐Armitage and logistic regression examined temporal trends and likelihood of undergoing NACT versus adjuvant chemotherapy based on patient age and molecular subtype. RESULTS: Overall, 96,622 patients met study criteria; 25% received NACT and 75% underwent surgery first, with comparable 5‐year estimates of overall survival (0.90, 95% CI 0.892–0.905 vs 0.91, 95% CI 0.907–0.913). During the study period, utilization of NACT increased from 14% to 36% and varied according to molecular subtype (year*molecular subtype p < 0.001, p‐corrected < 0.001). Women with HER2+ (OR 4.17, 95% CI 3.70–4.60, p < 0.001, p‐corrected < 0.001) and TNBC (OR 3.81, 95% CI 3.38–4.31, p < 0.001, p‐corrected < 0.001) were more likely to receive NACT over time, without a change in use among those with HR+ disease (OR 1.58, 95% CI 0.88–2.87, p = 0.13, p‐corrected = 0.17). CONCLUSION: Among women with early‐stage triple‐negative and HER2+ breast cancers, utilization of NACT increased over time, a trend that correlates with previously reported improved rates of pCR and options post‐neoadjuvant treatment with residual disease. Future research is needed to better understand multidisciplinary decisions for NACT and implications for breast cancer patients.
format Online
Article
Text
id pubmed-8855910
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88559102022-02-25 Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer Prakash, Ipshita Neely, N. Ben Thomas, Samantha M. Sammons, Sarah Blitzblau, Rachel C. DiLalla, Gayle A. Hyslop, Terry Menendez, Carolyn S. Plichta, Jennifer K. Rosenberger, Laura H. Fayanju, Oluwadamilola M. Hwang, E. Shelley Greenup, Rachel A. Cancer Med Clinical Cancer Research BACKGROUND: Controversy exists regarding the optimal sequence of chemotherapy among women with operable node‐negative breast cancers with high‐risk tumor biology. We evaluated national patterns of neoadjuvant chemotherapy (NACT) use among women with early‐stage HER2+, triple‐negative (TNBC), and high‐risk hormone receptor‐positive (HR+) invasive breast cancers. METHODS: Women ≥18 years with cT1‐2/cN0 HER2+, TNBC, or high recurrence risk score (≥31) HR+ invasive breast cancers who received chemotherapy were identified in the National Cancer Database (2010–2016). Cochran‐Armitage and logistic regression examined temporal trends and likelihood of undergoing NACT versus adjuvant chemotherapy based on patient age and molecular subtype. RESULTS: Overall, 96,622 patients met study criteria; 25% received NACT and 75% underwent surgery first, with comparable 5‐year estimates of overall survival (0.90, 95% CI 0.892–0.905 vs 0.91, 95% CI 0.907–0.913). During the study period, utilization of NACT increased from 14% to 36% and varied according to molecular subtype (year*molecular subtype p < 0.001, p‐corrected < 0.001). Women with HER2+ (OR 4.17, 95% CI 3.70–4.60, p < 0.001, p‐corrected < 0.001) and TNBC (OR 3.81, 95% CI 3.38–4.31, p < 0.001, p‐corrected < 0.001) were more likely to receive NACT over time, without a change in use among those with HR+ disease (OR 1.58, 95% CI 0.88–2.87, p = 0.13, p‐corrected = 0.17). CONCLUSION: Among women with early‐stage triple‐negative and HER2+ breast cancers, utilization of NACT increased over time, a trend that correlates with previously reported improved rates of pCR and options post‐neoadjuvant treatment with residual disease. Future research is needed to better understand multidisciplinary decisions for NACT and implications for breast cancer patients. John Wiley and Sons Inc. 2022-01-05 /pmc/articles/PMC8855910/ /pubmed/34989142 http://dx.doi.org/10.1002/cam4.4517 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Prakash, Ipshita
Neely, N. Ben
Thomas, Samantha M.
Sammons, Sarah
Blitzblau, Rachel C.
DiLalla, Gayle A.
Hyslop, Terry
Menendez, Carolyn S.
Plichta, Jennifer K.
Rosenberger, Laura H.
Fayanju, Oluwadamilola M.
Hwang, E. Shelley
Greenup, Rachel A.
Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer
title Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer
title_full Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer
title_fullStr Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer
title_full_unstemmed Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer
title_short Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer
title_sort utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855910/
https://www.ncbi.nlm.nih.gov/pubmed/34989142
http://dx.doi.org/10.1002/cam4.4517
work_keys_str_mv AT prakashipshita utilizationofneoadjuvantchemotherapyinhighrisknodenegativeearlybreastcancer
AT neelynben utilizationofneoadjuvantchemotherapyinhighrisknodenegativeearlybreastcancer
AT thomassamantham utilizationofneoadjuvantchemotherapyinhighrisknodenegativeearlybreastcancer
AT sammonssarah utilizationofneoadjuvantchemotherapyinhighrisknodenegativeearlybreastcancer
AT blitzblaurachelc utilizationofneoadjuvantchemotherapyinhighrisknodenegativeearlybreastcancer
AT dilallagaylea utilizationofneoadjuvantchemotherapyinhighrisknodenegativeearlybreastcancer
AT hyslopterry utilizationofneoadjuvantchemotherapyinhighrisknodenegativeearlybreastcancer
AT menendezcarolyns utilizationofneoadjuvantchemotherapyinhighrisknodenegativeearlybreastcancer
AT plichtajenniferk utilizationofneoadjuvantchemotherapyinhighrisknodenegativeearlybreastcancer
AT rosenbergerlaurah utilizationofneoadjuvantchemotherapyinhighrisknodenegativeearlybreastcancer
AT fayanjuoluwadamilolam utilizationofneoadjuvantchemotherapyinhighrisknodenegativeearlybreastcancer
AT hwangeshelley utilizationofneoadjuvantchemotherapyinhighrisknodenegativeearlybreastcancer
AT greenuprachela utilizationofneoadjuvantchemotherapyinhighrisknodenegativeearlybreastcancer